Home / Lifestyle / Health & Fitness / Article /
US FDA approves landmark pancreatic cancer drug that's shown to improve survival
Updated On: 27 August, 2026 06:49 PM IST | Washington | AP
FDA officials gave expedited approval to the first-of-a-kind pill, called daraxonrasib, that blocks a mutated protein that fuels tumour growth in more than 90 per cent of pancreatic cancer cases. It's an approach that previously eluded drugmakers for decades

Image for representational purpose only. Photo Courtesy: File pic
The Food and Drug Administration on Wednesday approved a groundbreaking new drug for the most common form of pancreatic cancer, offering US patients a more effective treatment against one of the deadliest types of cancer.
FDA officials gave expedited approval to the first-of-a-kind pill, called daraxonrasib, that blocks a mutated protein that fuels tumour growth in more than 90 per cent of pancreatic cancer cases. It's an approach that previously eluded drugmakers for decades.


